远程实施癌症基因检测的可及性促进试验(MAGENTA):一项随机临床试验
MAGENTA是一项4臂随机非劣效性试验,纳入3839名女性,评估远程基因检测中省略检测前和/或检测后个体化遗传咨询是否增加3个月和12个月时的痛苦。家族史队列主要分析显示所有实验组在3个月痛苦方面均非劣效,省略检测前咨询的两组检测完成率最高。
要点
- 在家族史队列中,省略检测前和/或检测后咨询的各实验组在3个月痛苦方面均非劣效。
- 3个月时焦虑、抑郁或决策后悔在各组间无统计学显著差异。
- 检测完成率最高的为两个未接受检测前咨询的组。
核心结论
- 在远程基因检测中,对所有参与者省略个体化检测前咨询、对无致病性变异者省略检测后咨询,在检测后痛苦方面不劣于对照,为遗传风险评估提供了替代照护模式。
研究设计与样本
- MAGENTA为4臂随机非劣效性试验,评估检测前和/或检测后个体化遗传咨询对参与者检测后3个月和12个月痛苦的影响。
- 参与者通过社交媒体和传统媒体招募,入组时间为2017年4月27日至2020年9月29日。
- 纳入标准为30岁及以上、英语 speaking、美国居民、能上网并有医疗保健专业人员的女性;既往癌症基因检测或咨询为排除标准。
- 家族史队列参与者有乳腺癌或卵巢癌个人史或家族史;家族性致病性变异(PV)队列参与者报告有1名生物学亲属在可干预癌症易感基因中携带PV。
- 数据分析于2020年12月13日至2023年5月31日进行。
主要发现
- 在家族史队列的主要分析中,所有实验组在3个月痛苦方面均非劣效。
- 3个月时焦虑、抑郁或决策后悔在各组间无统计学显著差异。
- 检测完成率最高的为两个未接受检测前咨询的组。
关键数值与推荐
- 主要结局为收到结果后3个月时由事件影响量表测量的参与者痛苦。
- 次要结局包括检测完成率、焦虑、抑郁和决策后悔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. OBJECTIVE: To assess whether omitting pretest and/or posttest genetic counseling would increase distress during remote testing. DESIGN, SETTING, AND PARTICIPANTS: Making Genetic Testing Accessible (MAGENTA) was a 4-arm, randomized noninferiority trial testing the effects of individualized pretest and/or posttest genetic counseling on participant distress 3 and 12 months posttest. Participants were recruited via social and traditional media, and enrollment occurred between April 27, 2017, and September 29, 2020. Participants were women aged 30 years or older, English-speaking, US residents, and had access to the internet and a health care professional. Previous cancer genetic testing or counseling was exclusionary. In the family history cohort, participants had a personal or family history of breast or ovarian cancer. In the familial pathogenic variant (PV) cohort, participants reported 1 biological relative with a PV in an actionable cancer susceptibility gene. Data analysis was performed between December 13, 2020, and May 31, 2023. INTERVENTION: Participants completed baseline questionnaires, watched an educational video, and were randomized to 1 of 4 arms: the control arm with pretest and/or posttest genetic counseling, or 1 of 3 study arms without pretest and posttest counseling. Genetic counseling was provided by phone appointments and testing was done using home-delivered saliva kits. MAIN OUTCOMES AND MEASURES: The primary outcome was participant distress measured by the Impact of Event Scale 3 months after receiving the results. Secondary outcomes included completion of testing, anxiety, depression, and decisional regret. RESULTS: A total of 3839 women (median age, 44 years [range 22-91 years]), most of whom were non-Hispanic White and college educated, were randomized, 3125 in the family history and 714 in the familial PV cohorts. In the primary analysis in the family history cohort, all experimental arms were noninferior for distress at 3 months. There were no statistically significant differences in anxiety, depression, or decisional regret at 3 months. The highest completion rates were seen in the 2 arms without pretest counseling. CONCLUSIONS AND RELEVANCE: In the MAGENTA clinical trial, omitting individualized pretest counseling for all participants and posttest counseling for those without PV during remote genetic testing was not inferior with regard to posttest distress, providing an alternative care model for genetic risk assessment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02993068.
引用
- Swisher EM, Rayes N, Bowen D, et al. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37707822. doi:10.1001/jamaoncol.2023.3748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。